sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
|
thrombolytics
|
REFLUDAN
|
NONE
|
Lepirudin_ddi.xml
|
DDI-DrugBank.d52.s0
|
DDI-DrugBank.d52.s0.p1
|
WelChol was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
|
metoprolol
|
quinidine
|
NONE
|
Colesevelam_ddi.xml
|
DDI-DrugBank.d551.s1
|
DDI-DrugBank.d551.s1.p15
|
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
|
ciprofloxacin
|
theophylline
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s16
|
DDI-DrugBank.d123.s16.p7
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
angiotensin-converting enzyme inhibitors
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p17
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
disulfiram
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p17
|
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
|
theophylline
|
CGS21680
|
EFFECT
|
7746025.xml
|
DDI-MedLine.d51.s4
|
DDI-MedLine.d51.s4.p0
|
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
|
HMG-CoA reductase inhibitors
|
simvastatin
|
NONE
|
11197581.xml
|
DDI-MedLine.d25.s12
|
DDI-MedLine.d25.s12.p8
|
Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
|
Nafazodone
|
Xanax
|
ADVISE
|
Adinazolam_ddi.xml
|
DDI-DrugBank.d449.s1
|
DDI-DrugBank.d449.s1.p2
|
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
|
aspirin
|
Nalfon
|
MECHANISM
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s2
|
DDI-DrugBank.d154.s2.p9
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
diazepam
|
Valium
|
NONE
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p18
|
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
|
theophylline
|
phenytoin
|
MECHANISM
|
3967572.xml
|
DDI-MedLine.d7.s1
|
DDI-MedLine.d7.s1.p0
|
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
|
miconazole
|
hypoglycemic agents
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s9
|
DDI-DrugBank.d178.s9.p0
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
Antacids
|
aluminum
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p4
|
For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
|
anticoagulants
|
vitamin K
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s3
|
DDI-DrugBank.d64.s3.p2
|
Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
|
Quinolones
|
warfarin
|
EFFECT
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s24
|
DDI-DrugBank.d516.s24.p4
|
Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
|
Amphetamines
|
antihypertensives
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s11
|
DDI-DrugBank.d158.s11.p2
|
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
|
magnesium
|
Ibandronate
|
MECHANISM
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s1
|
DDI-DrugBank.d440.s1.p8
|
Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
|
diltiazem
|
rifampin
|
ADVISE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s42
|
DDI-DrugBank.d565.s42.p0
|
In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
|
broad-spectrum antibiotics
|
contraceptives
|
EFFECT
|
Clavulanate_ddi.xml
|
DDI-DrugBank.d419.s5
|
DDI-DrugBank.d419.s5.p1
|
Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
|
Aripiprazole
|
aripiprazole
|
NONE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s16
|
DDI-DrugBank.d509.s16.p1
|
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
|
macrolide antibiotics
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s3
|
DDI-DrugBank.d450.s3.p12
|
Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
|
ethchlorvynol
|
amitriptyline HCl
|
EFFECT
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s26
|
DDI-DrugBank.d99.s26.p0
|
ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
|
caffeine
|
combination hormonal contraceptives
|
NONE
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s43
|
DDI-DrugBank.d485.s43.p3
|
In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
|
dirithromycin
|
theophylline
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s13
|
DDI-DrugBank.d522.s13.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
sulfamethoxazole
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p52
|
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
|
ketoconazole
|
cisapride
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s7
|
DDI-DrugBank.d165.s7.p0
|
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
|
BREVIBLOC
|
norepinephrine
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s15
|
DDI-DrugBank.d422.s15.p2
|
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
|
thiazides
|
vitamin D
|
EFFECT
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s5
|
DDI-DrugBank.d404.s5.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
cimetidine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p2
|
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.
|
nimodipine
|
omega-agatoxin VIA
|
NONE
|
11137351.xml
|
DDI-MedLine.d58.s7
|
DDI-MedLine.d58.s7.p13
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
saquinavir
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p8
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
NSAID
|
methotrexate
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p10
|
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
|
PROLEUKIN
|
dacarbazine
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s5
|
DDI-DrugBank.d114.s5.p1
|
Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
|
piperazine
|
phenothiazine
|
EFFECT
|
Piperazine_ddi.xml
|
DDI-DrugBank.d326.s0
|
DDI-DrugBank.d326.s0.p2
|
Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
|
Erythromycin
|
astemizole
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s10
|
DDI-DrugBank.d397.s10.p2
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
antihistamines
|
Tegretol
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p63
|
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
|
tricyclic antidepressants
|
anticholinergic
|
EFFECT
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s20
|
DDI-DrugBank.d99.s20.p0
|
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
codeine
|
alcohol
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s0
|
DDI-DrugBank.d398.s0.p0
|
Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
|
hydrochlorothiazide
|
anionic exchange resins
|
MECHANISM
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s4
|
DDI-DrugBank.d162.s4.p9
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Oruvail
|
nabumetone
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p187
|
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
|
anesthetics
|
INAPSINE
|
EFFECT
|
Droperidol_ddi.xml
|
DDI-DrugBank.d254.s0
|
DDI-DrugBank.d254.s0.p14
|
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
|
Clonidine hydrochloride
|
sedatives
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s1
|
DDI-DrugBank.d495.s1.p2
|
In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
|
warfarin
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s17
|
DDI-DrugBank.d382.s17.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
anesthetics
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p29
|
If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
|
bitolterol
|
steroid
|
ADVISE
|
Bitolterol_ddi.xml
|
DDI-DrugBank.d560.s1
|
DDI-DrugBank.d560.s1.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cinchophen
|
influenza virus vaccine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p593
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
antibiotics
|
colistin
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p35
|
Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
|
steroids
|
aspirin
|
EFFECT
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s14
|
DDI-DrugBank.d526.s14.p2
|
The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
|
tetracycline
|
methoxyflurane
|
EFFECT
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s5
|
DDI-DrugBank.d500.s5.p1
|
Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
|
Clidinium
|
phenothiazines
|
EFFECT
|
Clidinium_ddi.xml
|
DDI-DrugBank.d322.s1
|
DDI-DrugBank.d322.s1.p0
|
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
|
bromocriptine mesylate
|
haloperidol
|
EFFECT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s2
|
DDI-DrugBank.d272.s2.p1
|
Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
|
amprenavir
|
methadone
|
MECHANISM
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s10
|
DDI-DrugBank.d437.s10.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
aminoglycosides
|
sodium colistimethate
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p33
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
aspirin
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p1
|
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
|
HMG-CoA reductase inhibitor
|
spironolactone
|
ADVISE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s17
|
DDI-DrugBank.d140.s17.p1
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
coumarin
|
digitoxin
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p33
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
clofibrate
|
methyldopa
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p637
|
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
|
heparin
|
Activase
|
EFFECT
|
Alteplase_ddi.xml
|
DDI-DrugBank.d508.s1
|
DDI-DrugBank.d508.s1.p4
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
SSRIs
|
fluoxetine
|
NONE
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s10
|
DDI-DrugBank.d386.s10.p3
|
Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
|
L-histidine
|
medroxyprogesterone acetate
|
EFFECT
|
L-Histidine_ddi.xml
|
DDI-DrugBank.d365.s0
|
DDI-DrugBank.d365.s0.p2
|
Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
|
aprepitant
|
diltiazem
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s41
|
DDI-DrugBank.d382.s41.p4
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
haloperidol
|
tramadol
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p729
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Theo-Dur
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p42
|
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
|
eplerenone
|
erythromycin
|
MECHANISM
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s3
|
DDI-DrugBank.d20.s3.p0
|
Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
|
Aminoglutethimide
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s6
|
DDI-DrugBank.d485.s6.p0
|
Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
|
Heparin Sodium
|
droperidol
|
NONE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s7
|
DDI-DrugBank.d488.s7.p1
|
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
|
CANCIDAS
|
efavirenz
|
ADVISE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s14
|
DDI-DrugBank.d350.s14.p0
|
Valproate: Felbatol causes an increase in steady-state valproate concentrations.
|
Felbatol
|
valproate
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s22
|
DDI-DrugBank.d434.s22.p2
|
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
|
atorvastatin
|
ethinyl estradiol
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s10
|
DDI-DrugBank.d140.s10.p6
|
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
|
theophylline
|
quinolone
|
MECHANISM
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s0
|
DDI-DrugBank.d427.s0.p0
|
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
|
progestin
|
rifampin
|
EFFECT
|
Norethindrone_ddi.xml
|
DDI-DrugBank.d306.s0
|
DDI-DrugBank.d306.s0.p5
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
indinavir
|
cisapride
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p6
|
Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
|
Cimetidine
|
nicardipine HCl
|
MECHANISM
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s2
|
DDI-DrugBank.d468.s2.p2
|
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
|
cyclosporine
|
cyclosporine
|
NONE
|
16649344.xml
|
DDI-MedLine.d118.s3
|
DDI-MedLine.d118.s3.p5
|
Ketoconazole: Concomitant use of ketoconazole is contraindicated.
|
Ketoconazole
|
ketoconazole
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s9
|
DDI-DrugBank.d558.s9.p0
|
Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
|
thyroid products
|
tricyclic antidepressants
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s15
|
DDI-DrugBank.d54.s15.p4
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
antidepressants
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p0
|
Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
|
Amphetamines
|
corticosteroid
|
INT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s29
|
DDI-DrugBank.d236.s29.p0
|
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
|
clozapine
|
paroxetine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s22
|
DDI-DrugBank.d480.s22.p4
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Cholestyramine
|
fat soluble vitamins
|
MECHANISM
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s0
|
DDI-DrugBank.d384.s0.p27
|
Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
|
nonsteroidal anti-inflammatory drugs
|
methotrexate
|
MECHANISM
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s5
|
DDI-DrugBank.d415.s5.p5
|
However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
|
INDOCIN
|
anticoagulant
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s6
|
DDI-DrugBank.d82.s6.p0
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
calcium
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p3
|
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
|
Tagamet
|
theophylline
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s4
|
DDI-DrugBank.d171.s4.p0
|
The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
|
fluconazole
|
glipizide
|
INT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s11
|
DDI-DrugBank.d225.s11.p0
|
Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
|
CRIXIVAN
|
itraconazole
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s78
|
DDI-DrugBank.d97.s78.p0
|
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
|
docetaxel
|
erythromycin
|
MECHANISM
|
Docetaxel_ddi.xml
|
DDI-DrugBank.d371.s1
|
DDI-DrugBank.d371.s1.p3
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
selective serotonin reuptake inhibitors
|
sumatriptan succinate
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p2
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
procainamide
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p8
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
lidocaine
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p7
|
Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
|
acetaminophen
|
caffeine
|
EFFECT
|
3969689.xml
|
DDI-MedLine.d55.s0
|
DDI-MedLine.d55.s0.p0
|
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
|
INSPRA
|
ACE inhibitors
|
EFFECT
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s6
|
DDI-DrugBank.d20.s6.p7
|
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
erythromycin
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s2
|
DDI-DrugBank.d237.s2.p10
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
rifampin
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p39
|
Antacids may interfere with the absorption of LEVSIN.
|
Antacids
|
LEVSIN
|
MECHANISM
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s1
|
DDI-DrugBank.d142.s1.p0
|
Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
|
probenecid
|
cefdinir
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s4
|
DDI-DrugBank.d420.s4.p8
|
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
|
Nabilone
|
diazepam
|
EFFECT
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s1
|
DDI-DrugBank.d552.s1.p0
|
Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
|
REMICADE
|
anakinra
|
EFFECT
|
Infliximab_ddi.xml
|
DDI-DrugBank.d45.s1
|
DDI-DrugBank.d45.s1.p2
|
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
|
quinolone antimicrobial
|
warfarin
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s4
|
DDI-DrugBank.d347.s4.p5
|
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
|
Corticotropin
|
diuretic
|
EFFECT
|
Cosyntropin_ddi.xml
|
DDI-DrugBank.d439.s0
|
DDI-DrugBank.d439.s0.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.